Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Control of Regulatory T Cell Development by the Transcription Factor Foxp3

2003 • 7,902 citations

Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells

2010 • 5,969 citations

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

1995 • 5,124 citations

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

2006 • 2,516 citations

CD4+CD25+ suppressor T cells: more questions than answers

2002 • 2,202 citations

Toll Pathway-Dependent Blockade of CD4 ⁺ CD25 ⁺ T Cell-Mediated Suppression by Dendritic Cells

2003 • 2,023 citations

Regulatory T cells, tumour immunity and immunotherapy

2006 • 2,009 citations

Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma

2002 • 1,454 citations

Immune surveillance of tumors

2007 • 1,325 citations

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

2006 • 1,180 citations

Survivin, cancer networks and pathway-directed drug discovery

2007 • 973 citations

CD4⁺CD25⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

2004 • 854 citations

Infectious immunological tolerance.

1971 • 811 citations

Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells

2004 • 680 citations

Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma

2005 • 618 citations

The anticancer immune response: indispensable for therapeutic success?

2008 • 556 citations

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

2001 • 504 citations

Replicative adenoviruses for cancer therapy

2000 • 424 citations

Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes

1977 • 337 citations

Oncolytic viruses in cancer therapy

2007 • 332 citations

Survival prediction in terminal cancer patients: a systematic review of the medical literature

2000 • 287 citations

Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF

2010 • 225 citations

Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients

2010 • 213 citations

Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.

2002 • 186 citations

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

2006 • 184 citations

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus

2003 • 168 citations

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.

1988 • 168 citations

Terminal cancer

2000 • 150 citations

Toll-like Receptor 9 Triggers an Innate Immune Response to Helper-dependent Adenoviral Vectors

2007 • 133 citations

Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes

2007 • 116 citations

Immunosuppression Enhances Oncolytic Adenovirus Replication and Antitumor Efficacy in the Syrian Hamster Model

2008 • 116 citations

Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study

2007 • 111 citations

Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors

2010 • 111 citations

Integrin targeted oncolytic adenoviruses Ad5‐D24‐RGD and Ad5‐RGD‐D24‐GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors

2011 • 96 citations

Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset.

1987 • 96 citations

Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer

1998 • 94 citations

Immunostimulatory Effects of Low-Dose Cyclophosphamide Are Controlled by Inducible Nitric Oxide Synthase

2005 • 86 citations

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors

2010 • 70 citations

In situ adenovirus vaccination engages T effector cells against cancer

2009 • 53 citations

Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies

2008 • 48 citations

Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir

2010 • 38 citations

Oncolytic adenovirus treatment of a patient with refractory neuroblastoma

2010 • 35 citations

Impaired T Cell Receptor Signaling in Foxp3⁺ CD4 T Cells

2007 • 29 citations

Live viruses in cancer treatment.

2002 • 27 citations

Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care

2010 • 24 citations

Immunomodulatory effect of cyclophosphamide on host humoral immunity in Dunning's R-3327 adenocarcinoma of the prostate

1991 • 4 citations